Zinzino AB Reports Robust Growth and Increased Dividend in 2025 Year-End Report

Zinzino AB 2025 Year-End Report Overview

Zinzino AB, a notable player in the health and wellness sector, has released its Year-End Report for 2025, highlighting impressive financial growth and strategic advancements. The company reported its revenue for the fourth quarter amounting to SEK 1,035.3 million, representing a remarkable 45% increase compared to last year's similar period.

This growth is attributed not only to strong customer demand but also to the effective integration of recent acquisitions, which have bolstered Zinzino’s market presence. Zinzino's impressive financial performance has positioned it well within the competitive landscape of the health industry, particularly due to its flagship product, BalanceOil, which is essential for providing needed omega-3 fatty acids to consumers.

Financial Highlights

In the fourth quarter alone, Zinzino saw revenues climb to SEK 1,035.3 million, up from SEK 713.5 million in the previous year. This reflects a consistent upward trend seen throughout the year, with local currency revenue increasing by 52%, showcasing the company's ability to navigate market fluctuations effectively.

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the quarter reached SEK 175.2 million, significantly above the SEK 72.9 million recorded last year. This increase in EBITDA margin to 16.9% from 10.2% is chiefly due to enhanced gross profit figures and greater operational synergies realized through the acquisition of Zurvita, a health and nutrition company.

For the calendar year 2025, Zinzino's total revenue stood at SEK 3,337.5 million, showcasing a staggering 51% increase from SEK 2,207.8 million the previous year. This growth was mirrored in their EBITDA, which reached SEK 443.4 million, a substantial rise from SEK 250.7 million, and the overall EBITDA margin improved to 13.3% from 11.4%.

Shareholder Rewards

Reflecting on this success, Zinzino's Board of Directors proposed a 50% increase in dividends from SEK 4.00 to SEK 6.00 per share, offering an enticing return to shareholders. This decision underscores the company’s strong financial foundation and commitment to enhancing shareholder value. The proposed dividend is predicted to total SEK 217.9 million prior to any dilution due to shares issuance linked to new acquisitions.

Strategic Acquisitions

Zinzino has been proactive in expanding its operational reach, notably through the acquisition of 35% of shares in Xion International Group, which focuses on sustainable algae cultivation for omega-3 production. Additionally, Zinzino acquired assets from Sanki, strengthening its distribution channels across North and South America.

The launch of the Gut Health Test further enriches the company’s product portfolio, driving consumer engagement and promoting a holistic approach to health.

Future Outlook

The company expresses confidence in its trajectory, especially following recent expansions into new markets, including upcoming operations in Peru set to launch in February 2026. Zinzino aims to tap into new consumer bases, enhancing its global footprint.

Zinzino continues to distinguish itself within the wellness industry, driven by a commitment to research and development, quality product offerings, and an unwavering focus on customer satisfaction. As it moves into 2026, stakeholders remain optimistic about the company's path forward, bolstered by a robust financial performance and strategic growth initiatives.

For more detailed financial metrics and operational plans, the complete Year-End Report is accessible through Zinzino’s official website and other investor communications.